Published in:
Open Access
01-10-2015 | Short Communication
Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus
Authors:
Gianluca Tornese, Veronica Tisato, Lorenzo Monasta, Liza Vecchi Brumatti, Giorgio Zauli, Paola Secchiero
Published in:
Acta Diabetologica
|
Issue 5/2015
Login to get access
Excerpt
TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily, which plays an important role in regulating cell death and inflammation. Beyond its anti-tumor activity, increasing evidence in animal studies suggests that TRAIL plays a role in the control of autoimmune diseases, and in particular in type 1 diabetes mellitus (T1DM) [
1,
2]. In this context, in a previous study carried out in a retrospective cohort of T1DM pediatric patients, we found significant lower levels of circulating TRAIL in T1DM patients with respect to healthy age-matched controls [
3]. However, a limitation of our previous study was as follows: (1) the lack of serial serum samples harvested from the same patients at different time post onset and (2) the lack of information about concurrent metabolic status at time of blood sampling. …